Thrombotic thrombocytopenic purpura (TTP) is a rare, severe blood disorder that causes blood clots to form in small blood vessels. TTP can affect children and adults. People may inherit the ...

Purpose. A case of a patient who developed thrombotic thrombocytopenic purpura (TTP) after consuming a weight-loss product containing green tea is reported. Summary. A 38-year-old, 68-kg Caucasian ...

Acquired thrombotic thrombocytopenic purpura (aTTP) affects the way your blood clots and helps cause bleeding. Learn what causes aTTP and how to spot the symptoms.

Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare disorder in which blood clots form in small blood vessels throughout your body. These clots can cause serious, potentially life ...

Congenital thrombotic thrombocytopenic purpura (cTTP) results from a deficiency in ADAMTS13 ... FDA approves first treatment for patients with rare inherited blood clotting disorder.

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

Thrombotic thrombocytopenic purpura was diagnosed in a neonate with hereditary ADAMTS13 deficiency. Treatment with recombinant ADAMTS13 reversed the deficiency, and the child’s development at 2 ...

GC1126A is designed to treat the rare blood disorder. GC Biopharma Corp. announced that GC1126A has been granted orphan drug designation by FDA. This will provide certain incentives, such as tax ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

Thrombotic thrombocytopenic purpura (TTP) and immune thrombocytopenia (ITP) are both blood disorders. Learn more about the similarities and differences between TTP and ITP.

OSAKA, Japan & CAMBRIDGE, Mass., August 07, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADZYNMA® (recombinant ADAMTS13) for the treatment of ...